Table 1.

Epitopes identified in N-protein—IgG antibodies.

Peptide numberPeptide sequenceCOVID-19 acuteCOVID-19 convalescentsPre-pandemic
1MSDNGPQNQRNAPRITFGGP****ns
2RPQGLPNNTASWFTALTQHGnsnsns
3IGYYRRATRRIRGGDGKMKD**ns*
4LNTPKDHIGTRNPANNAAIVnsnsns
5GSQASSRSSSRSRNSSRNST**nsns
6NQLESKMSGKGQQQQGQTVTnsnsns
7RRGPEQTQGNFGDQELIRQGnsnsns
8IAQFAPSASAFFGMSRIGMEnsnsns
9SDSTGSNQNGERSGARSKQR****ns**
10LKFPRGQGVPINTNSSPDDQnsnsns
11GTGPEAGLPYGANKDGIIWVnsnsns
12LQLPQGTTLPKGFYAEGSRGnsnsns
13TPGSSRGTSPARMAGNGGDAnsnsns
14KKSAAEASKKPRQKRTATKA*********
15GDQELIRQGTDYKHWPQIAQnsnsns
16DPNFKDQVILLNKHIDAYKTnsnsns
17FPPTEPKKDKKKKADETQAL*nsns
18LDDFSKQLQQSMSSADSTQAnsnsns
19KADETQALPQRQKKQQTVTL*****ns
20GDAALALLLLDRLNQLESKMnsnsns
Peptide numberPeptide sequenceCOVID-19 acuteCOVID-19 convalescentsPre-pandemic
1MSDNGPQNQRNAPRITFGGP****ns
2RPQGLPNNTASWFTALTQHGnsnsns
3IGYYRRATRRIRGGDGKMKD**ns*
4LNTPKDHIGTRNPANNAAIVnsnsns
5GSQASSRSSSRSRNSSRNST**nsns
6NQLESKMSGKGQQQQGQTVTnsnsns
7RRGPEQTQGNFGDQELIRQGnsnsns
8IAQFAPSASAFFGMSRIGMEnsnsns
9SDSTGSNQNGERSGARSKQR****ns**
10LKFPRGQGVPINTNSSPDDQnsnsns
11GTGPEAGLPYGANKDGIIWVnsnsns
12LQLPQGTTLPKGFYAEGSRGnsnsns
13TPGSSRGTSPARMAGNGGDAnsnsns
14KKSAAEASKKPRQKRTATKA*********
15GDQELIRQGTDYKHWPQIAQnsnsns
16DPNFKDQVILLNKHIDAYKTnsnsns
17FPPTEPKKDKKKKADETQAL*nsns
18LDDFSKQLQQSMSSADSTQAnsnsns
19KADETQALPQRQKKQQTVTL*****ns
20GDAALALLLLDRLNQLESKMnsnsns

Immunoreactivity of each sequence in the group was tested against the threshold calculated for the whole group using one-way ANOVA and the Dunnett’s multiple comparison test (α = 0.05): *P  < .05; **P  < .01; ***P < .001; ****P < .0001.

Table 1.

Epitopes identified in N-protein—IgG antibodies.

Peptide numberPeptide sequenceCOVID-19 acuteCOVID-19 convalescentsPre-pandemic
1MSDNGPQNQRNAPRITFGGP****ns
2RPQGLPNNTASWFTALTQHGnsnsns
3IGYYRRATRRIRGGDGKMKD**ns*
4LNTPKDHIGTRNPANNAAIVnsnsns
5GSQASSRSSSRSRNSSRNST**nsns
6NQLESKMSGKGQQQQGQTVTnsnsns
7RRGPEQTQGNFGDQELIRQGnsnsns
8IAQFAPSASAFFGMSRIGMEnsnsns
9SDSTGSNQNGERSGARSKQR****ns**
10LKFPRGQGVPINTNSSPDDQnsnsns
11GTGPEAGLPYGANKDGIIWVnsnsns
12LQLPQGTTLPKGFYAEGSRGnsnsns
13TPGSSRGTSPARMAGNGGDAnsnsns
14KKSAAEASKKPRQKRTATKA*********
15GDQELIRQGTDYKHWPQIAQnsnsns
16DPNFKDQVILLNKHIDAYKTnsnsns
17FPPTEPKKDKKKKADETQAL*nsns
18LDDFSKQLQQSMSSADSTQAnsnsns
19KADETQALPQRQKKQQTVTL*****ns
20GDAALALLLLDRLNQLESKMnsnsns
Peptide numberPeptide sequenceCOVID-19 acuteCOVID-19 convalescentsPre-pandemic
1MSDNGPQNQRNAPRITFGGP****ns
2RPQGLPNNTASWFTALTQHGnsnsns
3IGYYRRATRRIRGGDGKMKD**ns*
4LNTPKDHIGTRNPANNAAIVnsnsns
5GSQASSRSSSRSRNSSRNST**nsns
6NQLESKMSGKGQQQQGQTVTnsnsns
7RRGPEQTQGNFGDQELIRQGnsnsns
8IAQFAPSASAFFGMSRIGMEnsnsns
9SDSTGSNQNGERSGARSKQR****ns**
10LKFPRGQGVPINTNSSPDDQnsnsns
11GTGPEAGLPYGANKDGIIWVnsnsns
12LQLPQGTTLPKGFYAEGSRGnsnsns
13TPGSSRGTSPARMAGNGGDAnsnsns
14KKSAAEASKKPRQKRTATKA*********
15GDQELIRQGTDYKHWPQIAQnsnsns
16DPNFKDQVILLNKHIDAYKTnsnsns
17FPPTEPKKDKKKKADETQAL*nsns
18LDDFSKQLQQSMSSADSTQAnsnsns
19KADETQALPQRQKKQQTVTL*****ns
20GDAALALLLLDRLNQLESKMnsnsns

Immunoreactivity of each sequence in the group was tested against the threshold calculated for the whole group using one-way ANOVA and the Dunnett’s multiple comparison test (α = 0.05): *P  < .05; **P  < .01; ***P < .001; ****P < .0001.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close